EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 237 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era June 11, 2020 Young Man’s “Water You Can Eat” Invention for His Grandma with... July 8, 2020 For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions June 3, 2021 An Increase in Healthcare Costs Associated with the Use of Multigene... February 14, 2024 Load more HOT NEWS ESMO Calls for Cancer to Be at the Core of the... Will politics keep us from accessing EU science funding? Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients... FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR...
